Investopedia12d
Novartis Posts Results Above Estimates, Raises Outlook
Novartis posted third-quarter results that beat analysts' estimates and raised its full-year outlook, buoyed by strong sales of drugs like breast-cancer treatment Kisqali. The Swiss pharmaceutical ...
Benzinga.com23d
European Medicines Agency's Panel Supports Approval Of Novartis' Kisqali In Patients With Early-Breast Cancer
EMA's CHMP issued a positive opinion for Novartis' Kisqali for high-risk early breast cancer. Kisqali showed a 25.1% reduced risk of cancer recurrence in Phase 3 NATALEE trial. The CHMP ...
Spectrum News NY11mon
FDA expands use of breast cancer drug Kisqali
The FDA recently expanded the approval of the breast cancer drug Kisqali to treat patients with earlier stages of the disease. Thousands of women diagnosed with early-stage breast cancer will have ...
Pharmabiz22d
EMA committee recommends marketing approval for Novartis’ Kisqali to help reduce risk of recurrence in people with HR+/HER2- early breast cancer
Novartis announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion and recommended granting marketing authorization ...
Hosted on MSN22d
Novartis (NVS) to Report Q3 Earnings: What's in the Offing?
Breast cancer drug Kisqali’s sales surged in the first half ... the average earnings surprise being 10.53%. GSK PLC GSK has an Earnings ESP of +6.79% and a Zacks Rank #3. GSK topped earnings ...